PRESS RELEASE published on 04/11/2023 at 14:30, 1 year 5 months ago Patient Enrollment Surpasses 90% in Jaguar Health's Pivotal Phase 3 OnTarget Trial of Crofelemer for Cancer Therapy-Related Diarrhea
PRESS RELEASE published on 04/06/2023 at 14:30, 1 year 5 months ago Jaguar Health Provides Update on Monitoring Trading Activity to Identify Possible Illegal Short Selling
PRESS RELEASE published on 03/30/2023 at 14:30, 1 year 5 months ago Jaguar Animal Health Exhibiting at Veterinary Cancer Society Collaborative Conference for Canalevia-CA1, the Company's FDA Conditionally Approved Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs
PRESS RELEASE published on 03/27/2023 at 13:00, 1 year 6 months ago Jaguar Health Reports 2022 Financial Results - Prescription Revenues up 179% to $11.9 Million
PRESS RELEASE published on 03/24/2023 at 18:30, 1 year 6 months ago Jaguar Health Announces Time Change for March 27th Investor Webcast to 8:00 AM EDT
PRESS RELEASE published on 03/23/2023 at 13:30, 1 year 6 months ago Leading Cancer Patient Advocate Kelly Shanahan, M.D., Joins Jaguar Health's Scientific Advisory Board
PRESS RELEASE published on 03/21/2023 at 13:30, 1 year 6 months ago Jaguar Health to Hold Investor Webcast Monday, March 27th at 8:30 AM EDT Regarding Q4 2022 Financials & Corporate Updates
PRESS RELEASE published on 03/15/2023 at 13:30, 1 year 6 months ago Jaguar Health Celebrates U.N. International Day of Forests with Milestone of Providing Income to 20,000+ People Living in Tropical Rainforest Communities
PRESS RELEASE published on 03/13/2023 at 13:30, 1 year 6 months ago Jaguar Health Leveraging AI to Support Patient Access to Mytesi, the Company's FDA-Approved Prescription Drug
PRESS RELEASE published on 03/02/2023 at 14:30, 1 year 6 months ago Jaguar Health to Present at BioTrinity 2023 Conference’s R&D Spotlight on Rare Diseases
Published on 09/28/2024 at 02:06, 1 day 3 hours ago Global Education Communities Corp. Reports Second Tranche Closing of Non-Brokered Private Placement
Published on 09/28/2024 at 02:00, 1 day 3 hours ago bettermoo(d)’s Moodrink(TM) Featured in Banners of Well-Known Canadian Retailers
Published on 09/28/2024 at 00:10, 1 day 5 hours ago LQWD Technologies Announces Non-Brokered Private Placement Update
Published on 09/28/2024 at 14:01, 15 hours 26 minutes ago Turkiye Garanti Bankasi A.S.: Explanation on Subordinated Debt Securities to Qualified Investors
Published on 09/27/2024 at 22:30, 1 day 6 hours ago DREAM Pivotal Study Data Presented at the International Surgical Sleep Society 2024 Educational Update
Published on 09/27/2024 at 21:56, 1 day 7 hours ago EQS-Adhoc: FDA grants approval for Stelara® Biosimilar FYB202/OtulfiTM (ustekinumab-aauz)
Published on 09/27/2024 at 18:50, 1 day 10 hours ago PETROFAC ANNOUNCES IN-PRINCIPLE AGREEMENT ON FINANCIAL RESTRUCTURE
Published on 09/27/2024 at 18:40, 1 day 10 hours ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 09/27/2024 at 17:45, 1 day 11 hours ago NFL BIOSCIENCES: 2024 FIRST-HALF BUSINESS AND EARNINGS UPDATE
Published on 09/26/2024 at 18:00, 2 days 11 hours ago GUILLEMOT CORPORATION: Availability of the interim financial report to June 30, 2024
Published on 09/26/2024 at 18:00, 2 days 11 hours ago GUILLEMOT CORPORATION: 2024 CONSOLIDATED INTERIM RESULTS
Published on 09/26/2024 at 17:47, 2 days 11 hours ago imerys-26-September-2024-information-share-capital-and-voting-rights-as-of-31-August-2024